Pharmaceuticals in Brazil

Pharmaceuticals in Brazil industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

 Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Brazil

 Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Brazil

 Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

 Add weight to presentations and pitches by understanding the future growth prospects of the Brazil pharmaceuticals market with five year forecasts

Synopsis

Essential resource for top-line data and analysis covering the Brazil pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy

 What was the size of the Brazil pharmaceuticals market by value in 2015?

 What will be the size of the Brazil pharmaceuticals market in 2020?

 What factors are affecting the strength of competition in the Brazil pharmaceuticals market?

 How has the market performed over the last five years?

 Who are the top competitors in Brazil’s pharmaceuticals market?

Key Highlights

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.

The Brazilian pharmaceuticals market had total revenues of USD 13.9bn in 2015, representing a compound annual growth rate (CAGR) of 9.5% between 2011 and 2015.

A large generic shift is expected in the next few years as significant increases in government spending on free and heavily-subsidized drugs will decelerate as the government shifts its focus to cost-containment, coupled with many big patents expiring.

The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.7% for the five-year period 2015-2020, which is expected to drive the market to a value of USD 19.2bn by the end of 2020.